Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Ritlecitinib on Oral Contraceptive PK
NCT03608241Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ritlecitinib tosilate in alopecia areata (2 arms), sponsored by Pfizer. Primary endpoints: Area Under the Curve From Time Zero to Extrapolated Infinite Time for Ethinyl Estradiol at 48 hours and Area Under the Curve From Time Zero to Extrapolated Infinite Time for Levonogestrel at 48 hours. Started Sep 2018; status: completed.
02
Drugs
ritlecitinib tosilate
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT03608241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03608241.